Pacific Bio (NASDAQ: PACB) reported Q3 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $38.4 million versus the consensus estimate of $40.13 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.